MEDICAL CROSSFIRE®: SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD): OPTIMIZING THE DIAGNOSIS AND MANAGEMENT THROUGH MULTIDISCIPLINARY, PATIENT-CENTERED CARE

Released On
December 31, 2018

Expires On
December 31, 2019

Media Type
Internet

Completion Time
90 minutes

Specialty
Pulmonology

Topic(s)
Interstitial Lung Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC.

 

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward pulmonologists, rheumatologists, dermatologists, clinical immunologists, allergists, specialty nurse practitioners, physician assistants, primary care clinicians, and other healthcare professionals involved in the treatment of SSc-ILD.

Program Overview

During this Medical Crossfire®, a panel of expert faculty will review the pathophysiology, disease course, and burden of a SSc-ILD diagnosis, as well as the predictors of mortality and disease progression. The panel will also discuss diagnostic modalities and challenges associated with making a diagnosis in the setting of SSc-ILD, as well as current and emerging therapies. Finally, the panel will talk about team-based strategies to optimize the overall management of SSc-ILD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the pathophysiology of SSc-ILD and the implications that new insights have for diagnosing and treating the disease
  • Identify key risk factors for SSc-ILD to improve early symptom recognition and prognosis of the disease
  • Analyze key data on new and emerging treatment options for SSc-ILD to properly educate patients
  • Implement team-based strategies to improve individualization of treatment plans for patients with SSc-ILD

Faculty

Monique Hinchcliff, MD, MS

Associate Professor of Medicine
Department of Rheumatology, Allergy and Clinical Immunology
Director of Clinical Research
Director of Yale Scleroderma Program
New Haven, Connecticut

Ganesh Raghu, MD, FACP, FCCP

Director: Center for Interstitial Lung Diseases
Co-Director: Scleroderma Clinic
University of Washington Medical Center

Professor of Medicine and Laboratory Medicine
University of Washington
Seattle, Washington

Lesley Ann Saketkoo, MD, MPH

Director
New Orleans Scleroderma & Sarcoidosis Patient Care & Research Center
New Orleans, Louisiana
Tulane Director
University Medical Centre (UMC) - Comprehensive Pulmonary Hypertension Center (CPHC)

Associate Professor of Medicine
Tulane University School of Medicine
Clinical Immunology, Allergy and Rheumatology
Pulmonary Diseases, Critical Care and Environmental Medicine
New Orleans, Louisiana

Carolyn Spada RN, BSN

Nurse Coordinator
University of Washington Center for Interstitial Lung Disease
Seattle, Washington

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and is a provider approved by the California Board of Registered Nursing (CBRN).

Credit Designation Statement

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following contributors have relevant financial relationships with commercial interests to disclose:

Monique Hinchcliff, MD, MS

  • No financial information to disclose

Ganesh Raghu

  • Consultant: Boehringer Ingelheim Pharmaceuticals, Inc. and Roche-Genentech
  • Investigational/Off-Label Use of Drugs/Devices Disclosure: Pirfenidone, Nintedanib, Mycophenolate

Lesley Ann Saketkoo, MD, MPH

  • No financial information to disclose

Carolyn Spada RN, BSN

  • No financial information to to disclose

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer/Disclosure of Unlabeled Use

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.